Holen Sie sich die Stockscreener-App
1.31
5.76%
-0.08
Handel nachbörslich:
1.30
-0.01
-0.76%
Schlusskurs vom Vortag:
$1.39
Offen:
$1.39
24-Stunden-Volumen:
40,467
Relative Volume:
0.01
Marktkapitalisierung:
$10.28M
Einnahmen:
$598.00K
Nettoeinkommen (Verlust:
$-44.93M
KGV:
-0.1576
EPS:
-8.31
Netto-Cashflow:
$-17.32M
1W Leistung:
+12.93%
1M Leistung:
-3.68%
6M Leistung:
-32.82%
1J Leistung:
-72.99%
1-Tages-Spanne:
$1.29
$1.39
1-Wochen-Bereich:
$1.13
$1.40
52-Wochen-Spanne:
$1.08
$14.40
Ernexa Therapeutics Inc Stock (ERNA) Company Profile
Firmenname
Ernexa Therapeutics Inc
Sektor
Branche
Telefon
(617) 798-6700
Adresse
1035 CAMBRIDGE STREET, CAMBRIDGE
Vergleichen Sie ERNA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ERNA
Ernexa Therapeutics Inc
|
1.31 | 10.91M | 598.00K | -44.93M | -17.32M | -8.31 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.86 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
796.55 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
398.29 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
788.49 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.97 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Ernexa Therapeutics Inc Aktie (ERNA) Neueste Nachrichten
Is Ernexa Therapeutics Inc. stock trading at a premium valuationJuly 2025 Pullbacks & Technical Pattern Alert System - ulpravda.ru
How Ernexa Therapeutics Inc. stock reacts to inflationary pressures2025 Price Momentum & Daily Price Action Insights - ulpravda.ru
How Ernexa Therapeutics Inc. stock compares to industry benchmarksCPI Data & Low Risk High Win Rate Picks - ulpravda.ru
Ernexa’s stem cell therapy could soon enter ovarian cancer trials - Rare Cancer News
Ernexa Therapeutics announces successful pre-Ind FDA meeting - MarketScreener
Ernexa receives FDA alignment for ovarian cancer cell therapy By Investing.com - Investing.com Canada
Ernexa Therapeutics Advances Ovarian Cancer Treatment Toward First-in-Human Trial After FDA Meeting - Quiver Quantitative
Ernexa Therapeutics Announces Successful Pre-IND FDA Meeting and Continues Progress Toward First-in-Human Trial in Ovarian Cancer - Yahoo Finance
Will Ernexa Therapeutics Inc. stock pay special dividends2026 world cup usa national team group stage key players possession football group prediction preview - ulpravda.ru
Published on: 2026-01-02 17:34:55 - moha.gov.vn
Is Ernexa Therapeutics Inc. stock attractive for growth ETFsEarnings Growth Report & Technical Confirmation Trade Alerts - DonanımHaber
How Ernexa Therapeutics Inc. stock performs in rate cut cyclesQuarterly Earnings Report & Expert Curated Trade Setups - DonanımHaber
Ernexa Therapeutics (NASDAQ:ERNA) Stock Price Down 5.1% – Here’s What Happened - Defense World
Ernexa Therapeutics Earnings Notes - Trefis
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
Ernexa Therapeutics stock falls after ASH meeting presentation By Investing.com - Investing.com Australia
Ernexa Therapeutics stock falls after ASH meeting presentation - Investing.com
Ernexa reports promising preclinical data for cancer cell therapy By Investing.com - Investing.com Australia
Ernexa Therapeutics Presents New Preclinical Data on ERNA-101 at ASH Annual Meeting Highlighting Innovative Cell Therapy Potential to Combat Cancer - Quiver Quantitative
Ernexa reports promising preclinical data for cancer cell therapy - Investing.com
Ernexa Therapeutics Presents New Preclinical Data at - GlobeNewswire
Ernexa Therapeutics (ERNA) Stock Analysis Report | Financials & Insights - Benzinga
With Ernexa Therapeutics Stock Sliding, Have You Assessed The Risk? - Trefis
Can Ernexa Therapeutics Stock Recover If Markets Fall? - Trefis
Ernexa Therapeutics Inc. (ERNA) 5.2% in After-hours: Strong Presentation Initiative - Stocks Telegraph
Ernexa Therapeutics announces oral presentation at the 67th American Society of Hematology - marketscreener.com
Ernexa Therapeutics Announces Oral Presentation at the 67th American Society of Hematology (ASH) Annual Meeting - GlobeNewswire
Can Ernexa Therapeutics Inc. stock hit analyst price targetsWeekly Stock Recap & AI Powered Trade Plan Recommendations - Newser
How Ernexa Therapeutics Inc. stock compares to market leadersTrade Analysis Summary & Verified Stock Trade Ideas - Newser
Ernexa Therapeutics Strengthens Scientific and Medical Advisory Board with Appointment of Leading Oncologist Dr. Ira S. Winer, M.D., Ph.D., FACOG - markets.businessinsider.com
Ernexa Therapeutics appoints oncologist Dr. Winer to advisory board By Investing.com - Investing.com Australia
Ernexa Therapeutics appoints oncologist Dr. Winer to advisory board - Investing.com
Ernexa Therapeutics Appoints Dr. Ira S. Winer to Scientific and Medical Advisory Board - Quiver Quantitative
Profit Review: How Ernexa Therapeutics Inc. stock compares to industry benchmarks2025 Historical Comparison & Fast Moving Trade Plans - BỘ NỘI VỤ
Contrasting Ernexa Therapeutics (NASDAQ:ERNA) & KalVista Pharmaceuticals (NASDAQ:KALV) - Defense World
How Ernexa Therapeutics Inc. stock reacts to oil pricesJuly 2025 Action & Fast Momentum Stock Entry Tips - newser.com
How to monitor Ernexa Therapeutics Inc. with trend dashboardsTrade Entry Summary & Low Risk Entry Point Tips - newser.com
Ernexa Therapeutics Inc. stock chart pattern explained2025 Market Outlook & Verified Momentum Stock Alerts - newser.com
Sector ETF performance correlation with Ernexa Therapeutics Inc.Gap Down & Free AI Powered Buy and Sell Recommendations - newser.com
Is it too late to sell Ernexa Therapeutics Inc.Earnings Risk Report & AI Enhanced Trading Alerts - newser.com
Will Ernexa Therapeutics Inc. bounce back from current supportGold Moves & Real-Time Stock Entry Alerts - newser.com
Why Ernexa Therapeutics Inc. stock could see breakout soonTrend Reversal & Weekly Setup with High ROI Potential - newser.com
Analyzing drawdowns of Ernexa Therapeutics Inc. with statistical toolsGap Down & Long-Term Safe Investment Plans - newser.com
Will Ernexa Therapeutics Inc. stock benefit from automationEntry Point & AI Powered Buy/Sell Recommendations - newser.com
Should I hold or sell Ernexa Therapeutics Inc. stock in 2025Forecast Cut & Free Growth Oriented Trading Recommendations - newser.com
Finanzdaten der Ernexa Therapeutics Inc-Aktie (ERNA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Ernexa Therapeutics Inc-Aktie (ERNA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Cherington Charles | 10% Owner |
Apr 02 '25 |
Buy |
0.10 |
3,768,397 |
394,174 |
20,401,602 |
0.90%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):